New drug tested to tame rare blood disorder in kids
NCT ID NCT04965636
Summary
This study tested whether a drug called mepolizumab, given as a shot under the skin, could help control a rare blood disorder called Hypereosinophilic Syndrome (HES) in children and teenagers aged 6 to 17. The main goal was to see if it could reduce the number of disease flare-ups over a year and allow participants to safely lower their steroid doses. The trial involved 16 young people who were already on standard care for HES.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPEREOSINOPHILIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Rochester, Minnesota, 55905, United States
-
GSK Investigational Site
Cincinnati, Ohio, 45229, United States
-
GSK Investigational Site
Cleveland, Ohio, 44106, United States
-
GSK Investigational Site
Charleston, South Carolina, 29425, United States
-
GSK Investigational Site
Buenos Aires, 1888, Argentina
-
GSK Investigational Site
Buenos Aires, C1028AAP, Argentina
-
GSK Investigational Site
Quilmes, 1878, Argentina
-
GSK Investigational Site
São Paulo, 05410-002, Brazil
-
GSK Investigational Site
Sorocaba, 18040-425, Brazil
-
GSK Investigational Site
Petah Tikva, 49202, Israel
-
GSK Investigational Site
Rotterdam, 3015 CE, Netherlands
-
GSK Investigational Site
Ankara, 6230, Turkey (Türkiye)
-
GSK Investigational Site
Izmir, 35100, Turkey (Türkiye)
-
GSK Investigational Site
Kayseri, 38039, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.